How a tiny biotech rebounded from bankruptcy and Martin Shkreli at the helm to convince the NIH to bet on its unproven coronavirus drug

How a tiny biotech rebounded from bankruptcy and Martin Shkreli at the helm to convince the NIH to bet on its unproven coronavirus drug

Summary List Placement

Among the scores of companies the US government is working with to find effective COVID-19 treatments, one biotech firm stands out.
Humanigen entered 2020 with two full-time employees, $214,000 in cash, and a history that included a b…

Read More…

You May Also Like